Skip to main content
. 2020 Apr 27;12(5):1087. doi: 10.3390/cancers12051087

Figure 2.

Figure 2

Inhibition of MDA-MB-231 cell viability by dasatinib, AZD-6244, and their combination. (A) The responses of MDA-MB-231 cells to dasatinib and AZD-6244 are compared to their response to the combination of both at equal molar concentrations; (B) isobolograms of AZD-6244 and dasatinib combination analysis at 50% inhibition; (C) isobolograms of AZD-6244 and dasatinib combination analysis at 70% inhibition. The results are representative of two independent experiments of triplicates.